| Name | Title | Contact Details |
|---|
Ambulatory care at Hotel Dieu Hospital (HDH) is specialized care that may include a scheduled visit to one or more hospital clinics, diagnostic or procedural areas. In some cases, a single health care professional, for example a surgeon or internal medicine physician, may see patients in a traditional clinic setting. Increasingly, patients and families will receive care in a team-based inter-disciplinary and/or inter-professional program, such as our pre-surgical screening, diabetes, breast assessment, bariatric, chronic pain or cardiac rehabilitation programs. Ambulatory care at HDH includes care for patients with urgent and less critical emergency problems at our Urgent Care Centre. Hotel Dieu Hospital has a very active ambulatory surgery program where most patients return home the same day. We also have a short-stay facility in the form of a satellite post-anesthetic care unit that supports patients who need extended time for pain control and rehabilitation therapy. This facility is key to our innovative fast-track total hip and knee arthroplasty program. Hotel Dieu Hospital is a faith-based, academic hospital where research and learning take place every day and where we are committed to partnership with patients and families. We actively engage in implementing innovative models of care that support patient care, as well as regional and academic health care needs. Affiliated with Queen`s University, we serve as a major teaching location for learners from across the Faculty of Health Sciences, including medical, nursing and allied health learners. And research at Hotel Dieu Hospital contributes to the growing field of knowledge about health care and ambulatory care in Canada and beyond. Ambulatory care at Hotel Dieu Hospital is part of an integrated, cost-effective system of health care in Southeastern Ontario.
K2M Group Holdings, Inc. is a global leader of complex spine and minimally invasive solutions focused on achieving three-dimensional Total Body Balance. Since its inception, K2M has designed, developed and commercialized innovative complex spine and minimally invasive spine technologies and techniques used by spine surgeons to treat some of the most complicated spinal pathologies. K2M has leveraged these core competencies into Balance ACS, a platform of products, services, and research to help surgeons achieve three-dimensional spinal balance across the axial, coronal and sagittal planes, with the goal of supporting the full continuum of care to facilitate quality patient outcomes. The Balance ACS platform, in combination with the Company’s technologies, techniques and leadership in the 3D-printing of spinal devices, enable K2M to compete favorably in the global spinal surgery market.
Provista is a Irving, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
R G I Medical Manafacturing Inc is a Gainesville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Smith & Nephew is a global advanced medical technology business. We support healthcare professionals in more than 100 countries to improve the quality of life for their patients. Since 1856, when our founder T.J. Smith developed a new method for refining cod liver oil, and in World War One when his nephew led the supply of wound care products, to the present day, Smith & Nephew continues to pioneer health solutions. Through our market leadership positions in Sports Medicine, Trauma, Orthopaedic Reconstruction and Advanced Wound Management, our 16,000 employees continue to improve outcomes and expand access, constantly striving to create value for healthcare professionals, patients, payers and shareholders. Annual sales in 2016 were more than $4.6 billion. We are a constituent of the UK’s FTSE100 and our shares are traded on London Stock Exchange and through American Depository Receipts on the New York Stock Exchange We have leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma. We have almost 11,000 employees and a presence in more than 90 countries. Annual sales in 2013 were more than $4.3 billion. We are a constituent of the UK's FTSE100 and our shares are traded on the London Stock Exchange and through American Depository Receipts on the New York Stock Exchange (LSE: SN, NYSE: SNN)